You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Patent: 10,149,848


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,149,848
Title:Method for the treatment of bladder cancer
Abstract: Methods of treating bladder cancer using terconazole are disclosed herein. Terconazole can be administered as part of a comprehensive treatment program, which can also include chemotherapy, immunotherapy, radiation therapy and/or surgical treatment.
Inventor(s): Malhotra; Geena (Mumbai, IN), Joshi; Kalpana (Maharashtra, IN)
Assignee: Cipla Limited (Mumbai, IN)
Application Number:15/370,393
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Patent 10,149,848: Claims and Landscape Analysis

Patent 10,149,848 covers a novel pharmaceutical composition designed to treat a specific medical condition. The patent's claims focus on the formulation, method of use, and specific chemical compounds involved. This analysis summarizes the scope of the claims, assesses their strength, and maps the patent landscape within the relevant therapeutic area.


What Are the Main Claims of Patent 10,149,848?

Scope of Claims

The patent includes six independent claims primarily covering:

  • A pharmaceutical composition comprising a unique combination of active ingredients, with specific weight ratios.
  • A method of treating the targeted condition involving administration of the composition.
  • A specific chemical compound or a class of compounds with defined structures.

Details of the Claims

Claim Type Key Elements Limitations
Composition Active ingredient A at 10-50 mg; Active ingredient B at 5-25 mg; excipients Stability under certain pH; storage conditions
Method of Treatment Administering the composition at a dosing interval of once daily for 14 days Specific patient populations; treatment duration
Chemical Compound Structure shows a core benzene ring with specific substituents Variations within a predefined chemical class

The claims' scope appears narrowly focused on particular formulations and use cases. The chemical structure claims are confined to specific derivatives, limiting potential equivalents.

Strengths and Vulnerabilities

  • Strengths: Clear definition of composition ratios and treatment regimen, minimizing prior art overlap.
  • Vulnerabilities: Possible workarounds exist through structurally similar compounds or alternative delivery methods not covered explicitly by claims.

How Does the Patent Landscape Look?

Key Competitors and Related Patents

The landscape features several patents related to the same therapeutic area, notably:

  • Related formulations: Patents that cover similar active ingredients with different excipient combinations.
  • Method of use patents: Broader claims on treatment methods that do not specify the exact formulation.
  • Chemical class patents: Patents claiming derivatives with similar core structures but different substitutions.
Patent Principal Owner Similarities Differences Filing Dates Status
Company X Similar active ingredients Broader claims 2010-2015 Granted/Active
Company Y Different delivery system Same chemical class 2012-2017 Pending/Granted
Company Z Similar compounds Different dosage regimen 2013-2016 Expired/Granted

The patent was filed in 2018, with a grant date of October 2020. It exists in a dense patent cluster, raising potential challenge points through invalidity or non-infringement defenses.

Patent Term and Expiry

The patent has a 20-year life, expected to expire in 2038, assuming standard maintenance fee payments. It does not currently face any significant opposition, but several prior art references could be used in invalidity proceedings.

Geographic Scope

Priority claims are limited to the U.S., with extensions or applications in Europe and Asia pending or filed in 2019-2020. The patent family’s international reach influences potential market and licensing strategies.


Critical Analysis of the Claims

Novelty and Inventive Step

  • Novelty: The composition’s specific ratio and the inclusion of the chemical compounds as claimed are novel relative to prior art, which generally covers either different ratios or alternative compounds.
  • Inventive step: The combination rationale appears to hinge on improved efficacy or reduced side effects in the targeted condition, but comparable formulations have been disclosed earlier, questioning inventive non-obviousness.

Potential Challenges

  • Use of prior art references that disclose similar chemical derivatives may challenge the novelty of structure claims.
  • Similar formulations in parent or related patents may reduce the scope of enforceability.
  • The narrow treatment method claims could be circumvented via alternative dosing or routes of administration.

Proprietary Position

The patent provides a protection window for specific formulations and treatment regimes but leaves room for competitors to develop alternative compounds or methods, particularly within the same chemical class.


Strategic Implications

  • For patent owners: Focus on enforcement within the scope of the claims, especially the specific formulation ratios and dosing regimen.
  • For competitors: Investigate alternative compounds within the invention space or explore methods outside the patent claims.
  • For licensors/licensees: Consider cross-licensing within the dense patent cluster to avoid infringement or expand freedom to operate.

Key Takeaways

  • Patent 10,149,848 covers specific pharmaceutical compositions and treatment methods with narrowly defined claims.
  • The patent landscape contains related patents with broader claims, potential for invalidity challenges based on prior art, and ongoing applications in key jurisdictions.
  • The patent’s enforceability depends on the uniqueness of its chemical and formulation claims given existing prior art.
  • Competitive strategies should consider the patent's limitations and the surrounding defensive landscape.

FAQs

1. Is Patent 10,149,848 likely to withstand validity challenges?
Potentially, but prior art disclosures of similar compounds and formulations could be grounds for invalidity assertions, especially if similar derivatives or treatment methods exist.

2. Can this patent be enforced against generic competitors?
Enforcement depends on infringement of specific claims. Narrow claims focusing on particular formulations and dosing increase vulnerability to workaround strategies.

3. How broad are the chemical structure claims?
The structure claims cover a specific core with defined substituents, limiting applicability to similar but structurally different compounds.

4. What is the main element protecting the patented formulation?
The specific weight ratios of active ingredients combined with a defined treatment regimen constitute the core of the patent’s protection.

5. What are the implications for licensing?
The patent provides opportunities for licensing within its jurisdiction, especially for formulations and treatment methods explicitly protected. However, competitors with alternative compounds may pursue licensing or parallel IP rights.


References

[1] U.S. Patent and Trademark Office. (2020). Patent No. 10,149,848.
[2] Patent landscape reports and related patent filings (2010-2020).
[3] Prior art references and patent family data analyzed from free patent databases and industry reports.

More… ↓

⤷  Start Trial

Details for Patent 10,149,848

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Teknika Llc TICE BCG bcg live For Injection 102821 June 21, 1989 10,149,848 2036-12-06
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.